Abstract:The E3 ubiquitin ligase adaptor Speckle-type POZ protein (SPOP) plays an important tumour suppressor role in prostate cancers (PCa), with mutation rate up to 15%. However, how SPOP mutations regulate prostate tumorigenesis remains elusive. Here, we report the identification of cell division cycle associated 5 (CDCA5) as a SPOP substrate. We found that SPOP interacts with CDCA5 and promotes its polyubiquitin degradation in a degron-dependent manner. This effect was greatly impaired by introducing PCa associated SPOP mutations. Importantly, we found that CDCA5 was essential for PCa cells to survive and proliferate. CDCA5 depletion in PCa cells led to cessation of proliferation, G2M arrest, severe sister chromatid aggregation disturbance, and apoptosis. we also found that CDCA5 knockdown decreased the protein expression of p-GSK3β, increased the activity of caspase-3, caspase-9, and the Bax/Bcl-2 ratio. Besides, we confirmed that CDCA5 interrupted cancer cell behavior via the AKT pathway. In contrast, silencing SPOP or overexpressing CDCA5 increased cell proliferation. Consistently, depleting SPOP along with CDCA5, or overexpressing CDCA5 along with SPOP also caused the growth of cells repressed. Consistent with the functional role of CDCA5, the mRNA and protein levels of CDCA5 were significantly increased in PCa, compared to normal tissues, and its high expression was associated with more severe lymph node metastasis, higher Gleason score, and poorer prognosis. Together, our data showed that SPOP plays a crucial role in inhibiting tumorigenesis and partly achieved this by promoting the degradation of oncoprotein CDCA5.

SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase.

SPOP in Cancer: Phenomena, Mechanisms and Its Role in Therapeutic Implications

Speckle-type POZ adaptor protein (SPOP) and its role in cancer

Prostate Cancer-Associated Mutation in SPOP Impairs Its Ability to Target Cdc20 for Poly-Ubiquitination and Degradation.

Tumor Suppressor SPOP Ubiquitinates and Degrades EglN2 to Compromise Growth of Prostate Cancer Cells.

SPOP Suppresses Pancreatic Cancer Progression by Promoting the Degradation of NANOG.

TGF- signaling regulates <i>SPOP</i> expression and promotes prostate cancer cell stemness

SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression

SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway

Speckle-type POZ protein suppresses hepatocellular carcinoma cell migration and invasion via ubiquitin-dependent proteolysis of SUMO1/sentrin specific peptidase 7

SPOP promotes ubiquitination and degradation of LATS1 to enhance kidney cancer progression

SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression.

The diverse roles of SPOP in prostate cancer and kidney cancer

Tumor Suppressor SPOP Mediates the Proteasomal Degradation of Progesterone Receptors (prs) in Breast Cancer Cells

SPOP promotes SIRT2 degradation and suppresses non-small cell lung cancer cell growth.

SPOP mutations promote p62/SQSTM1-dependent autophagy and Nrf2 activation in prostate cancer

Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP–HIPK2 axis

S119N Mutation of the E3 Ubiquitin Ligase SPOP Suppresses SLC7A1 Degradation to Regulate Hepatoblastoma Progression

The emerging role of SPOP protein in tumorigenesis and cancer therapy

SPOP point mutations regulate substrate preference and affect its function

Endometrial Cancer-Associated Mutants of SPOP Are Defective in Regulating Estrogen Receptor-Α Protein Turnover.